Antibody peptides as cancer vaccine-turning weapons to targets

Abstract

Stereotyped B-cell receptors (BCR) are frequent in patients with chronic lymphocytic leukemia (CLL). In cell culture and in mouse models of CLL, immunogenic epitopes of these BCRs were shown to trigger specific T-cell responses and to control leukemia development. These results suggest vaccination with autologous BCR-derived peptides as a novel therapy for CLL.